Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

Qiuni Chen; Yue Chen; Yijing Zhang; Lijuan Zhang; Kankan Chen; Zhengmei He; Chunling Wang; Liang Yu

doi:10.3389/fonc.2022.846044

Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes

Front Oncol. 2022 Apr 1:12:846044. doi: 10.3389/fonc.2022.846044. eCollection 2022.

Authors

Qiuni Chen^{1

2}, Yue Chen^{1

2}, Yijing Zhang^{1

2}, Lijuan Zhang^{1

2}, Kankan Chen^{1

2}, Zhengmei He^{1

2}, Chunling Wang^{1

2}, Liang Yu^{1

2}

Affiliations

¹ Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.
² Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.

Abstract

Background: Myelodysplastic syndromes (MDSs) are a very heterogeneous group of myeloid disorders with high prevalence and risk of developing acute myeloid leukemia. The more accurate risk stratification can provide a better guidance of treatment. The platelet-large cell ratio (P-LCR) is a parameter reported in complete blood cell count tests, and was associated with many diseases, but its role in MDS is not clear.

Purpose: This study aims to explore the impact of the P-LCR on the prognosis of patients with MDS, which is of great significance for clinical treatment.

Methods: In the retrospective study, 122 newly diagnosed MDS patients were enrolled. We used the bioinformatics tool X-tile to define a P-LCR threshold of 36.7% to predict prognosis. Patients were divided into P-LCR^low and P-LCR^high groups, and their characteristics were compared between the two groups.

Results: Results show that the P-LCR^low was associated with worse overall survival (OS) than the P-LCR^high patients (median OS, 18.53 months versus 25.77 months, p=0.0057), but there were no statistical differences in progression-free survival (PFS) between the two groups (p=0.2001). The results of univariate and multivariate Cox proportional hazard analyses adjusted for gender, bone marrow blast level, platelet count, and International Prognostic Scoring System scores showed that the P-LCR was useful in the evaluation of PFS [hazard ratio (HR) 0.212, 95%CI 0.064-0.702, p=0.011] and OS of MDS (HR 0.464, 95%CI 0.284-0.757, p=0.002).

Conclusion: This study is the first report showing that the P-LCR would be a simple and immediately available biomarker for predicting the prognosis of MDS.

Keywords: biomarker; myelodysplastic syndromes (MDS); platelet–large cell ratio (P-LCR); prognosis; survival.